Acute Ischemic Stroke
Conditions
Keywords
edaravone dexborneol, ischemic penumbra, NIHSS, mRS
Brief summary
The patients of acute ischemic stroke were divided into two groups, edaravone dexborneol treatment group and edaravone treatment group. The purpose of this study was to observe the changes of imaging and the improvement of NIHSS and mRS in different groups.
Detailed description
A total of 80 patients with acute ischemic stroke of middle cerebral artery were randomly divided into two groups, edaravone dexborneol treatment group and edaravone treatment group. The mismatch area between the low perfusion area of MRI 3D-ASL and the infarct area of DWI was defined as the ischemic penumbra, and the CBF perfusion pseudo color images with PLD of 1.5s and 2.5s were recorded. The above two CBF perfusion images were subtracted, and the residual area was quantitatively analyzed to reflect the establishment of collateral circulation. We aimed to observe whether there were differences in the improvement of ischemic penumbra and the establishment of collateral circulation between two groups after treatment. Besides, the improvment of NIHSS and mRS was also observed in different periods.
Interventions
DRUGedaravone dexborneol or edaravone
Edaravone dexborneol or edaravone is going to be used in two different groups to compare the efficacy.
Sponsors
Lili Cao
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Aged from 50 to 80 years old; 2. Patients diagnosed as acute ischemic stroke according to Chinese guidelines for the diagnosis and treatment of acute ischemic stroke 2018 and who met the requirements of middle cerebral artery blood supply area infarction (except deep perforator disease) without treatment; 3. Brain MR showed that the low perfusion area of ASL was at least 20% larger than that of DWI core infarct area, and the contralateral mirror brain tissue was basically normal; 4. NIHSS score was between 4 to 24; 5. Patient or their legal representatives were willing to sign the informed consent form.
Exclusion criteria
1. Serious mental abnormality, complicated with heart, lung, liver, renal insufficiency or malignant tumor and other serious diseases; 2. Combined with cerebral vascular malformation or cerebral hemorrhage; 3. Pregnant or lactating women; 4. Allergic to edaravone or dexborneol; 5. There are interactions between the drugs being taken by patients and the study drug or affect the clinical trial parameters.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| image changes in different groups | 7 days |
Secondary
| Measure | Time frame |
|---|---|
| NIHSS changes in different groups | 7days，14 days, 90 days |
| mRS changes in different groups | 7days，14 days, 90 days |
Countries
China
Contacts
Primary ContactYu-Qing Fang, MD
Outcome results
None listed